Respiratory company Vapotherm provides business update in response to COVID-19 pandemic - Gilde Healthcare

Respiratory company Vapotherm provides business update in response to COVID-19 pandemic

March 24, 2020

New Hampshire (United States) – Vapotherm, Inc. (NYSE: VAPO), the Gilde Healthcare company focused on the commercialization of its proprietary Hi-VNI Technology products that are used to treat patients suffering from respiratory distress, today announced an update on their business in response to the COVID-19 pandemic.

Vapotherm’s High Velocity Nasal Insufflation (HVNI) Technology, an advanced form of High Flow Oxygen therapy1, is a first-line therapy for COVID-19 patients who are struggling to breathe. The Journal of American Medical Association (JAMA) published research showing that 19% of COVID-19 patients are in respiratory distress and need some form of support to get the oxygen they need to stay alive.2 Our hospital customers are using our technology to support COVID-19 patients in mild to moderate respiratory distress, so that they can triage their sickest patients to a limited number of ventilators.

“At Vapotherm, customers and their patients are our total focus. Despite the challenging current environment, our entire team is working to support our hospital customers as they treat COVID-19 patients suffering with respiratory distress,” said Joe Army, President and CEO of Vapotherm. “We have seen a significant increase in demand for our products in Europe and have been preparing for similar increases in the United States. We are working diligently to increase our production of Precision Flow systems and disposables for use in treating this global pandemic.”

Vapotherm has seen significant increase in demand for Vapotherm Precision Flow® systems and single-use disposables as a result of COVID-19. The Company has been working to materially increase production capacity in its facility in New Hampshire, while ensuring the safety of employees at all times. Vapotherm has increased the number of production shifts and has identified additional opportunities to further increase manufacturing capacity in an effort to keep up with growing demand. This increased production is putting pressure on our supply chain and the Company is working with policy makers and suppliers to increase availability of critical parts to support production at these higher levels.

 

About Vapotherm
Vapotherm, Inc. (NYSE: VAPO) is a publicly traded developer and manufacturer of advanced respiratory technology based in Exeter, New Hampshire, USA. The company develops innovative, comfortable, non-invasive technologies for respiratory support of patients with chronic or acute breathing disorders. Over 2.1 million patients have been treated with Vapotherm Hi-VNI Technology. For more information, visit www.vapotherm.com.

About Hi-VNI® Technology
Hi-VNI® Technology is mask-free noninvasive ventilation for spontaneously breathing patients and a front-line tool for relieving respiratory distress—including hypercapnia, hypoxemia, and dyspnea. It allows for the fast, safe treatment of undifferentiated respiratory distress with one user-friendly tool. Hi-VNI Technology’s mask-free interface delivers optimally conditioned breathing gases, making it comfortable for patients and reducing the risks and care complexities associated with mask therapies. While being treated, patients can talk, eat, drink and take oral medication.

About Gilde Healthcare
Gilde Healthcare is a specialized European healthcare investor managing $ 1.5 billion across two fund strategies: venture & growth capital and private equity. Gilde Healthcare’s venture & growth capital fund invests in health tech and therapeutics. The venture & growth companies are based in Europe and North America. Gilde Healthcare’s private equity fund invests in profitable European lower mid-market healthcare companies with a focus on the Benelux and DACH region. The private equity fund targets healthcare providers, suppliers of medical products and service providers in the healthcare market. For more information, visit the company’s website at www.gildehealthcare.com.

Gilde Healthcare company Tagworks Pharmaceuticals Appoints Ken Mills as Chief Executive Officer

Biotech industry veteran to lead Tagworks as the company prepares to bring its novel platform and lead antibody-drug (ADC) conjugate program for solid tumors into the clinic in 2025 Founding CEO Marc Robillard, Ph.D., will...
October 1, 2024

Gilde Healthcare company Spire Health merges with Wellinks to form Industry Leader in Predictive Patient Care for Cardiopulmonary Health

Wellinks, the industry leader in virtual-led cardiopulmonary care, announced today it has merged with Spire Health in a non-cash transaction. The transaction merges Spire’s novel patient monitoring technology with Wellinks highly specialized virtual-led cardiopulmonary care model...
September 30, 2024

Gilde Healthcare company Big Health receives US FDA Clearance for DaylightRx

First FDA cleared non-drug treatment for generalized anxiety disorder. Clearance is the second FDA-clearance for Big Health. Big Health, a leading developer of digital mental health treatments, has been granted clearance by the U.S. Food...
September 5, 2024